Interne link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth april 14, 2025 om 11:00 AM UTC
Interne link ProQR Announces Year End 2024 Operating and Financial Results maart 13, 2025 om 11:00 AM UTC
Interne link ProQR Therapeutics Added to NASDAQ Biotechnology Index december 24, 2018 om 12:00 PM UTC
Interne link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 december 18, 2018 om 03:27 PM UTC
Interne link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 december 17, 2018 om 04:52 PM UTC
Interne link ProQR Announces Strategic Changes to the Management Team and Key New Hires december 13, 2018 om 12:00 PM UTC
Interne link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 december 10, 2018 om 12:00 PM UTC
Interne link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients december 04, 2018 om 12:00 PM UTC
Interne link ProQR to Present at the Evercore ISI HealthConX Conference november 20, 2018 om 12:00 PM UTC
Interne link ProQR Announces Financial Results for the Third Quarter of 2018 november 07, 2018 om 12:00 PM UTC
Interne link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference oktober 31, 2018 om 11:00 AM UTC
Interne link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals oktober 30, 2018 om 10:15 PM UTC
Interne link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals oktober 29, 2018 om 11:33 AM UTC
Interne link ProQR to Present at the Chardan Genetic Medicines Conference oktober 02, 2018 om 11:00 AM UTC
Interne link ProQR Announces Presentations at the OTS Annual Meeting september 24, 2018 om 11:00 AM UTC
Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares september 11, 2018 om 08:01 PM UTC
Interne link ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares september 07, 2018 om 08:21 AM UTC
Interne link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares september 05, 2018 om 08:01 PM UTC
Interne link ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3 september 05, 2018 om 09:46 AM UTC
Interne link ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial september 05, 2018 om 08:00 AM UTC
Interne link ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th augustus 15, 2018 om 11:00 AM UTC
Interne link ProQR Announces Financial Results for the Second Quarter of 2018 augustus 08, 2018 om 11:00 AM UTC
Interne link ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids augustus 01, 2018 om 11:00 AM UTC
Interne link ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July juli 12, 2018 om 11:00 AM UTC
Interne link ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa juni 28, 2018 om 11:00 AM UTC